RT Journal Article
SR Electronic
T1 The Utility of a Bayesian Predictive Model to Forecast Neuroinvasive West Nile Virus Disease in the United States, 2022
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.11.02.22281839
DO 10.1101/2022.11.02.22281839
A1 McCarter, Maggie S. J.
A1 Self, Stella
A1 Dye-Braumuller, Kyndall C.
A1 Lee, Christopher
A1 Li, Huixuan
A1 Nolan, Melissa S.
YR 2022
UL http://medrxiv.org/content/early/2022/11/04/2022.11.02.22281839.abstract
AB Arboviruses (arthropod-borne-viruses) are an emerging global health threat that are rapidly spreading as climate change, international business transport, and landscape fragmentation impact local ecologies. Since its initial detection in 1999, West Nile virus (WNV) has shifted from being a novel to an established arbovirus in the United States. Subsequently, more than 25,000 cases of West Nile Neuro-invasive Disease (WNND) have been diagnosed, cementing WNV as an arbovirus of public health importance. Given its novelty in the United States, high-risk ecologies are largely underdefined making targeted population-level public health interventions challenging. Using the Centers for Disease Control and Prevention ArboNET WNV data from 2000 – 2021, this study aimed to predict WNND human cases at the county level for the contiguous US states using a spatio-temporal Bayesian negative binomial regression model. The model includes environmental, climatic, and demographic factors, as well as the distribution of host species. An integrated nested LaPlace approximation (INLA) approach was used to fit our model. To assess model prediction accuracy, annual counts were withheld, forecasted, and compared to observed values. The validated models were then fit to the entire dataset for 2022 predictions. This proof-of-concept mathematical, geospatial modelling approach has proven utility for national health agencies seeking to allocate funding and other resources for local vector control agencies tackling WNV and other notifiable arboviral agents.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was financially supported by the Big Data Health Science Center at the University of South Carolina, and the United States Centers for Disease Control and Prevention (Cooperative Agreement Number U01CK000662).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study used only publicly available West Nile Virus counts from CDC's Arbonet.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are available upon reasonable request to the authors.